Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Taysha Gene Therapies Inc.
Headquarters: Dallas, TX, United States of America
Website: https://tayshagtx.com/
Year Founded: 2019
Status: Public
Industry Sector: HealthTechnology
CEO: Sean P. Nolan
Number Of Employees: 73
Enterprise Value: $357,197,548
PE Ratio: -4.52
Exchange/Ticker 1: NASDAQ:TSHA
Exchange/Ticker 2: N/A
Latest Market Cap: $352,603,392
BioCentury | Nov 13, 2024
Product Development
Adverse event casts shadow over Neurogene’s Rett syndrome readout
BioCentury’s Clinical Report also analyzes data from Syndax and Gan & Lee, plus pipeline updates from Sarepta, Tango and RAPT
BioCentury | Jun 29, 2024
Finance
Public Equity Report: Alumis slides after downsized IPO
Plus: Offerings by Zealand, Savara and Taysha; Savara’s PIPE; Grail reaches NASDAQ after Illumina separation
BioCentury | May 31, 2024
Regulation
Debating a new pathway for ultrarare
Woodcock, patient advocates, biotech leaders call for reforms
BioCentury | Mar 20, 2024
Product Development
Non-profit biotech aims to revive stalled ultrarare therapies
Orphan Therapeutics Accelerator will pursue hybrid non-profit, commercial model
BioCentury | Mar 5, 2024
Management Tracks
Promotions at Ally Bridge
Plus: Schreyer named CTO at Anagenex, and updates from 4M, Sitryx and Apollomics
BioCentury | Oct 18, 2023
Management Tracks
eTheRNA names Sagaert CEO, Dekkers as chairman
Plus: Cyrus Harmon becomes CEO at Vilya, and updates from Epic Bio, Exscientia, Pliant, Cognito, Pattern
BioCentury | Sep 20, 2023
Finance
Sept. 19 Quick Takes: RNA editing company Airna emerges with $30M round led by Arch
Plus: Longevity-focused VC debuts and updates from Recode, Merck, Taysha and Paratek
BioCentury | Aug 15, 2023
Deals
Aug. 14 Quick Takes: Second bidder drove up price in Biogen-Reata deal
Plus: Approval for Pfizer’s MM bispecific and updates from Harmony-Zynerba, One Bio-Hengrui, Taysha, Arcturus, BioXcel
BioCentury | Jul 21, 2023
Management Tracks
Ann Lee-Karlon named CEO of EpiBiologics
Plus: Haas becomes CEO at LimmaTech, and updates from Sagimet, Agenus, Triumvira and Passage Bio
BioCentury | Jul 10, 2023
Deals
July 10 Quick Takes: Astellas licenses 4D’s AAV vector
Plus: J&J partners with Nanobiotix and updates from CMS, WuXi, BeiGene and more
Items per page:
1 - 10 of 26